opioid management and rems principles: what would you do? james w. atchison, do (moderator) medical...
TRANSCRIPT
OPIOID MANAGEMENT and REMS PRINCIPLES:
WHAT WOULD YOU DO?
• JAMES W. ATCHISON, DO (MODERATOR)
• MEDICAL DIRECTOR• RIC CENTER FOR PAIN MANAGEMENT
DISTINGUISHED PANEL• STEVEN STANOS, DO
– SWEDISH MEDICAL CENTER, SEATTLE, WA
• BRIAN BRUEHL, MD– MD ANDERSON, HOUSTON, TX
• MICHAEL BRENNAN, MD– PAIN CENTER OF FAIRFIELD, FAIRFIELD, CT
• R. NORMAN HARDEN, MD– ANALGESIC RESEARCH CONSULTANTS, ATHENS, GA
DISCLOSURES• JAMES W. ATCHISON, DO
– SITE INVESTIGATOR, PFIZER/PARAXEL STUDY OF PREGABALIN FOR TRAUMATIC NERUOPATHIC PAIN
– MEDICAL REVIEW ACTIVTY – BEST DOSCTORS, INSPE
• STEVEN STANOS, DO– VERBAL DISCLOSURE
• MICHAEL BRENNAN, MD– SPEAKER/CONSULTANT
• PURDUE, TEVA, DEPOMED, ASTRZENECA, PERNIX, IROKO, KALEO, CAVA
– PRIOR STOCKHOLDER• CAVA
DISCLOSURES• BRIAN BRUEHL, MD
– CONSULTANT FOR MEDTRONIC NEUROMODULATION, SPINE AND RESTORATIVE THERAPIES
– CONSULTANT FOR BOSTON SCIENTIFIC NEUROMODULATION
– UNRESTRICTED RESEARCH SUPPORT FROM JAZZ PHARMACEUTICALS
– SITE PRIMARY INVESTIGATOR, JAZZ PHARMACEUTICALS (PRIZM STUDY)
• R. NORMAN HARDEN, MD– NO DISCLOSURES
LEARNING OBJECTIVES
• Participants will be able to:
– Direct patient education according to reference guidelines regarding safe prescribing, storage, and dose adjustments of opioids.
– Utilize concepts of rational polyp pharmacy in chronic pain management.
– Evaluate and recommend appropriate adjunct of treatments beyond medications for chronic pain management
REMS BLUEPRINT REVIEW• MAJOR HEADINGS
– Why Prescriber Education is Important– I. Assessing Patients for Treatment with
ER/LA Opioid Analgesic Therapy– II. Initiating Therapy, Modifying Dosing, and
Discontinuing Use of ER/LA Opioid Analgesics
– III. Managing Therapy with ER/LA Opioid Analgesics
04/21/23 presentation 6
REMS BLUEPRINT REVIEW
• MAJOR HEADINGS– IV. Counseling Patients and Caregivers
about the Safe Use of ER/LA Opioid Analgesics
– V. General Drug Information ER/LA Opioid Analgesic Products
– VI. Specific Drug Information
04/21/23 presentation 7
CASE PRESENTATION
• 48 y/o F presents for Tx w/ Hx of chronic Rt UL pain. S/P Fx of Radius & Ulna 2 y/a after fall. Pain level 5-8/10 ; referred due to completion of all w/u & Tx from ortho. Increased pain w/ all movements of arm and restricted use. Left knee pain w/ walking and standing tolerance of 25 minutes. Works as Administrative Assistant. Current Rx for Hydrocodone 5/325 to be used 1-2 q 4-6 hours as needed, and now taking 8 tabs per day. All records available for review.
04/21/23 presentation 8
WHAT WOULD YOU DO?
PROCESSES BEFORE RX
• Hx/visit includes Risk Stratification
• Review possible risks & side effects
• Review Patient Counseling Document
• Review/sign Patient Agreement
• Complete UDS
INITIAL RX?
1. Hydrocodone 5/325 up to 4/day
2. Hydrocodone 10/325 up to 4/day
3. Rotate to other Short Acting opioid
4. Transition to Long Acting opioid
5. No Rx on 1st visit
04/21/23 presentation 9
RISK STRATIFICATION
04/21/23 presentation 10
WHAT WOULD YOU DO?
COMMONLY USED TOOLS
• ORT
• SOAPP-R
• PSYCOLOGY INTERVIEW
• COMM
WHICH IS BEST?
04/21/23 presentation 11
REVIEW & SIGN PATIENT AGREEMENT
04/21/23 presentation 12
OPIOID ANALGESICS
• PATIENT AGREEMENTS– OPIOID THERAPY UTILIZED ONLY AFTER ALL
OTHER REASONABLE ATTEMPTS HAVE FAILED
– SINGLE PHYSICIAN PRESCRIBER & PHARMACY
– PT MUST AGREE TO COGNITIVE-BEHAVIORAL TX
– PRESCRIPTIONS MUST LAST UNTIL THE NEXT VISIT
• BRING IN ALL UNUSED MEDICATIONS
OPIOID ANALGESICS
• PATIENT AGREEMENT– PT MUST INFORM DOCTOR OF ALL OTHER
MEDICATIONS AND CHANGES• NO BENZOS OR CARISOPRODOL• ? PREGABLIN
– PT MUST AGREE TO RANDOM URINE TESTING
– INFORM PATIENT OF ALL RISKS (LIST)• INCLUDING TOLERANCE, DEPENDANCE, ADDICTION• SIDE EFFECTS
OPIOID ANALGESICS
• PATIENT AGREEMENT
– ANY EVIDENCE OF DRUG HOARDING, DRUG DIVERSION, UNAGREED-UPON DOSE CHANGES, LOSS OF RX, OR FAILURE TO FOLLOW THE AGREEMENT WILL (MAY?) RESULT IN TAPERING OF MEDICINE AND DISCONTINUATION OF DOCTOR-PATIENT RELATIONSHIP
• DESIGNED TO LIMIT DIVERSION
WHAT WOULD YOU DO?DO YOU REGULARLY USE THESE?
• YES
• NO
04/21/23 presentation 16
REVIEW RISKS AND SIDE EFFECTS OF OPIOIDS
04/21/23 presentation 17
Clinical Effects of Opioids
Circumstantial effects
Sedation Euphoria
Cough Suppression Decreased Bowel Motility
Undesirable effectsNausea/vomiting Urinary Retention
Mental Status Changes Respiratory Depression
Tolerance / Dry Mouth / Drug Dependence
Desirable effectsAnalgesia Relief of Anxiety
Mycek, et al., eds. Pharmacology, 2d ed. Philadelphia; Lippincott-Raven, 1997.
Opioid Adverse Effects
04/21/23 presentation 19
Usually dose related and some are drug specificCommon
ConstipationDry mouthNausea/VomitingSedationSweating
Less CommonRespiratory depressionBad dreams/hallucinationsDysphoria/deliriumMyoclonus/seizuresArrhythmiaPruritis/urticariaUrinary retentionAmenorrhea/sexual dysfunction
04/21/23 presentation 20
Anticipate/Manage Side Effects
Respiratory Depression- Sedation precedes respiratory depression
Role of sedation scales?- Respiratory rate alone is not an indication of respiratory function.- Use Naloxone sparingly
Respiratory depression reverses before analgesiaLimit to doses of 100 micrograms at a timeOne amp (0.4mg) in 4ml NS
Inject 1 ml at a time- can always give more.
WHAT WOULD YOU DO?
UPDATED HISTORY
• Continues Hydrocodone at 10/325 QID
• She experiences:– Constipation– Sleepiness in the afternoon– Occasional nausea – Occasional SOB
• She is not sleeping well at night
OPTIONS
• Add Colace, Sennakot, Miralax, etc, daily
• Start Provigil in am & noon• Use compazine PRN• Use Albuteral inhaler PRN• Start Clonazepam at HS?• Repeat UDS
04/21/23 presentation 21
REVIEW OF PATIENT COUNSELING DOCUMENT
04/21/23 presentation 22
Patient Counseling Document (PCD)
• The DOs and DON’Ts of Extended-Release / Long - Acting Opioid Analgesics
• DO: – Read the Medication Guide – Take your medicine exactly as prescribed – Store your medicine away from children and in a
safe place – Flush unused medicine down the toilet – Call your healthcare provider for medical advice
about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Patient Counseling Document (PCD)
• DON’T: Do not give your medicine to others Do not take medicine unless it was prescribed for you Do not stop taking your medicine without talking to your
healthcare provider Do not break, chew, crush, dissolve, or inject your
medicine. If you cannot swallow your medicine whole, talk to your healthcare provider.
Do not drink alcohol while taking this medicine
• For additional information go to: dailymed.nlm.nih.gov
Secure prescriptions the same way as other valuables in the home, like
jewelry or cash
•Take prescription medications out of the medicine cabinet and hide them in a place only you know about
•Encourage relatives and friends to secure their medications
•If possible, keep all medicines in a safe place
• An existing fire safe or gun safe
• Use a cut-proof bag designed for travel safety
• Locking medicine box or cabinet
Safe Storage of Opioids
APF. PainSAFE™. Problems with Opioids Can Be Prevented. Available at: http://www.painfoundation.org/painsafe/healthcare-professionals/pharmacotherapy/opioids/
preventing-problems.html. Accessed February 3, 2012.
SecureMonitor
45
OPIOID SAFETY
• STORAGE OF MEDICATIONS– LIMIT NUMBER OF PERSONS THAT ARE
AWARE YOU ARE USING PAIN MEDS• BE AWARE OF OTHER PATIENTS OR PERSONS
AROUND PHYSICIAN’S OFFICE• BE AWARE OF PERSONS WATCHING AT
PHARMACY• LIMIT DISCUSSIONS WITH FAMILY AND FRIENDS
– KEEP MEDS AWAY FROM FAMILY MEMBERS• DO NOT ASK THEM TO GET MEDICATIONS FROM
STORAGE
OPIOID SAFETY
• DATA FROM 2009-2010 National Survey on Drug Use and Health
– 70% of the 2.4 million Americans who abuse prescription drugs for the first time each year get them from friends and family
• 1/3 are teenagers
OPIOID SAFETY
• DATA FROM 2009-2010 National Survey on Drug Use and Health
– Casual Abusers of Rx Drugs(< 1x/wk)• 55% got substances FREE from friends/family• 11% PURCHASED substance from friends or
family• 5% TOOK WITHOUT PERMISSION
substances from family/friends
OPIOID SAFETY
• DATA FROM 2009-2010 National Survey on Drug Use and Health– Chronic Users/Abusers of Rx Drugs(>
1x/wk for more than a year)• 41% got substances WITH OR WITHOUT
PERMISSION from friends/family• 25% PURCHASED substance from dealer or
the internet• 25% OBTAINED THEM FROM A DOCTOR
WHAT WOULD YOU DO?
UPDATED HISTORY
• After 4 months, she calls into clinic for early refill as she is out of her pills and is not sure why?
OPTIONS
• Manage this over the phone until next visit
• Review Patient Agreement and DC from the clinic
• Review pharmacy issues• Review storage issues• Repeat UDS?
04/21/23 presentation 30
UDS MONITORING
04/21/23 presentation 31
WHAT WOULD YOU DO?
UDS RESULTS
• No Substances present?• Hydrocodone and
Hydromorphone present– w/ Oxymorphone– w/ benzodiazepine– w/ ETOH– w/ THC– w/ Cocaine– w/ Morphine, codeine, and
oxycodone
OPTIONS
• Repeat the test w/ Inc sensitivity – continue Tx
• Counsel pt and repeat at next visit – continue Tx
• Counsel pt and DC from clinic – Give 1 month Rx?
• Counsel pt and Refer to Addiction Medicine– Give 1 month Rx?
04/21/23 presentation 32
Choosing Opioid Therapy• Chronic pain management should be
individualized • Selection of a specific opioid based on criteria:
efficacy, tolerability, safety, and ease of use. • Initiated at a low dose and gradually increase-
monitor pain reduction and side effects. • Patients must be fully informed about the nature
of their treatment, benefits and harmful effects • Long acting versus breakthrough doses
WHAT WOULD YOU DO?
ADDITIONAL HISTORY
• Received Rx for Hydrocodone 10/325 QID for 6 months (compliant!).
• She previously split some pills in ½, but is now receiving less response to whole pills. Pain 7-9/10
• Having a difficulty time working.
OPTIONS1. Increase Hydrocodone to 6-
8 tabs/day
2. Rotate to other SA Opioid
3. Initiate LA/ER Opioid
4. Test UDS & Continue current Hydrocodone
5. Stop the medication
6. Refer to Addiction Medicine
7. Further Work-up?
04/21/23 presentation 34
ROTATING SA THERAPY
04/21/23 presentation 35
WHAT WOULD YOU DO?
SA OPTIONS
• Oxycodone– w/ Aceteminophen?
• Hydromorphone• Morphine Sulphate• Oxymorphone• Tapentadol
• How many MEQ?
OPTIONS
• Taper the Hydrocodone, then start new med
• Stop Hydrocodone; start new med at lower MEQ
• Stop Hydrocodone; start new med at same MEQ
• Stop Hydrocodone; start new med at Inc MEQ
04/21/23 presentation 36
DEPENDENCE IS NOT ADDICTION
• Physical dependence: – “Physical dependence is a state of
adaptation that is manifested by a drug class specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.”
DEPENDENCE IS NOT ADDICTION
• Addiction: – “Addiction is a primary, chronic, neurobiologic
disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations.
– It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving.”
OPIOID ANALGESICS
• TOLERANCE
– NEED FOR INCREASING AMOUNT OF THE DRUG TO ACHIEVE THE SAME EFFECT DUE TO THE PROGRESSIVE LOSS OF EFFECTIVENESS OF THE DRUG WITH ALL OTHER CONDITIONS CONSTANT
INITIATING LA THERAPY
04/21/23 presentation 40
WHAT WOULD YOU DO?
LA OPTIONS• Oxycontin
• MSContin/Oramorph/ MSER/Avinza
• Duragesic, Fentanyl Patch
• Opana ER
• Exalgo
• Nucynta ER
• Dolphine, Methadone
• Butrans Patch
• Zohydro ER, Hysingla ER
OPTIONS
• Taper the Hydrocodone, then start new med
• Stop Hydrocodone; start new med at lower MEQ
• Stop Hydrocodone; start new med at same MEQ
• Stop Hydrocodone; start new med at Inc MEQ
• Start new med and use Hydrocodone for BTP
04/21/23 presentation 41
WHAT WOULD YOU DO?
INFLUENCES
• Dosage Issues• Insurance coverage• Side Effects/History• Current Medications• Social History• REMS rules
START/DON’T START
• MS Contin• Fentanyl• Avinza• Oxycontin• Opana ER• Nucynta ER• Methadone• Butrans• Zohydro ER
04/21/23 presentation 42
INITIATING THERAPY OF ER/LA OPIOIDS
• According to Blueprint - may be used for initial dosing in non-tolerant pts.– Avinza 30 mg daily
– Butrans patch 5 mcg/hr every 7 days
– Dolophine 2.5-10 mg every 8-12 hours
– Embeda 20 mg/0.8 mg every 12-24 hours
– Nucynta ER 50 mg every 12 hours
– Opana ER 5 mg every 12 hours
– Oxycontin 10 mg every 12 hours
INITIATING THERAPY OF ER/LA OPIOIDS
• According to Blueprint - should not be used for initial dosing in non-tolerant pt– Duragesic patch– Exalgo– Kadian– MS Contin (?)
• Require a calculation of dose from current use – Based on conversion tables?
• There are increasing concerns with this!
INITIATING THERAPY OF ER/LA OPIOIDS
• According to Blueprint - Initial titration interval: – (minimum number of days before it
can be changed again)• Oxycontin – 1-2 days• Kadian – 2 days• MS Contin – 2 days• Opana ER – 2 days• Avinza – 3 days
INITIATING THERAPY OF ER/LA OPIOIDS
• According to Blueprint - Initial titration interval: – (minimum number of days before it
can be changed again)• Butrans – 3 days• Embeda – 3 days• Nucynta ER – 3 days• Duragesic – 72 hours• Exalgo – 3-4 days• Dolophine – Not reported – should be 7 days or
more
MODIFYING DOSING OF ER/LA OPIOIDS
• Titrate increase in ER/LA opioid medication on regular intervals– 25-33% changes for 1-2 visits– 10-20% for continuing visits
• Eventually titrate SA opioid to return to only PRN use
MODIFYING DOSING OF ER/LA OPIOIDS
• Stop further titration of ER/LA opioid when:– Adequate analgesic effects– Unacceptable side effects– No increase in analgesic response for 1
– 2 changes– Ceiling levels
• Avinza, Butrans, Nucynta, ?Dolphine
SIGNS/SYMPTOMS OF ONSETRESPIRATORY DEPRESSION
• Any Trouble Breathing– Hypopnea or apnea
• Cannot be easily aroused– Intoxicated behavior – confusion, slurred
speech, stumbling
• Unusual snoring, gasping, or snorting (especially with sleep)
• Fingertips/lips are blue/purple
SIGNS/SYMPTOMS OF ONSETRESPIRATORY DEPRESSION
• Recent Review Article in NEJM– Edward Boyer, MD, PhD
N Engl J Med 2012; 367; 146-155
• Internet Education/Assistance– Opioids911.org– Many Others
WHAT WOULD YOU DO?
WHAT ABOUT NALOXONE?
• I’ve thought about it!
• I regularly prescribe it!
• I don’t see the need for it!
04/21/23 presentation 51
ROTATING LA TREATMENT
04/21/23 presentation 52
WHAT WOULD YOU DO?
UPDATED HISTORY
• She returns a year later no better and wishes to change medications.
• Currently on Opana ER 40 mg q8h/MSIR 15 mg qid
• DC Opana ER; change to Duragesic Patch @ 100 mcg/hr
• DC Opana ER; start Oxycontin at 80 mg q12 h
• Begin tapering Opana ER by 10 mg per dose daily until off and then start MSER at 15 mg q 12 h
04/21/23 presentation 53
II. Initiating Therapy, Modifying Dosing, and Discontinuing Use of ER/LA Opioid Analgesics
• e. (LO3) Prescribers should understand the concept of incomplete cross-tolerance when converting patients from one opioid to another.
• f. (LO4) Prescribers should understand the concepts and limitations of equianalgesic dosing and follow patients closely during all periods of dose adjustments.
MODIFYING DOSING OF ER/LA OPIOIDS
• Equianalgesic Dosing– Based on Morphine Equivalents– Some meds much less reliable– Conversion Tables
• Lots of variability• May be cause of some deaths/injuries?
OPIOID DOSING:CONVERSION AND RISK
CONVERSION TO MORPHINE MEQ LOW MODERATE HIGH VERY HIGH
MORPHINE x 1 0 - 30 mg 31 - 100 mg 101 - 200 mg > 200 mg
HYDROCODONE x 1 0 - 30 mg 31 - 100 mg 101 - 200 mg > 200 mg
OXYCODONE x 1.5 0 - 20 mg 21 - 66 mg 67 - 133 mg > 133 mg
HYDROMORPHONE x 4 0 - 7.5 mg 7.6 - 25 mg 26 - 50 mg > 50 mg
OXYMORPHONE x 3 0 - 10 mg 11 - 33 mg 34 - 66 mg > 66 mg
TAPENTADOL x 0.33 0 - 75 mg 76 - 250 mg 251 - 500 mg > 500 mg
METHADONE x 3 0 - 10 mg 11 - 30 mg 31 - 60 mg > 60 mg
FENTANYL PATCH x 5 NONE 12 mcg/hr 24 - 50 mcg/hr > 50 mcg/hr
BUPRENORPHINE PATCH ? 0 - 35 mcg 36 - 52.5 mcg 52.6 - 105 mcg > 106 mcg
TRAMADOL ? 0 - 200 mg 201 - 400 mg > 400 mg
Methadone Conversion
04/21/23 presentation 57
Relative potency based on Morphine Equivalent dose per day- MEDD < 500mg, Conversion 5:1- MEDD < 1000mg, Conversion 10:1- MEDD > 1000mg Conversion 20:1
Ratios are starting points. Different variations in potency ratios
INCOMPLETE CROSS-TOLERANCE
• Current doses of ER/LA med not providing adequate analgesia– ?Tolerance vs Receptor responses
• A new/different ER/LA med may not have similar potency– Will act differently at the receptors
• Overdose is possible
MODIFYING DOSING OF ER/LA OPIOIDS
• Best Option– Taper current med to easier level
• Lower dose of current ER/LA med to make easier conversion
• Start new ER/LA with low dose of current med• Complete transition without change in SA opioid• Begin to increase new ER/LA • Still needs frequent FU due to inc pain
WHAT WOULD YOU DO?
UPDATED HISTORY
• Some concerns about the safety of storage and family members accessing the medications.
WHICH IS A TAMPER RESISTANT ER/LA OPIOID?
• Fentanyl Patches• Avinza (morphine)• Opana ER (oxymorphone)• Embeda (MS/Naltrexone)• Oxymorphone ER
04/21/23 presentation 60
CURRENTLY APPROVED ABUSE DETERRENT LA/ER
OPIOIDS• Oxycontin (Oxycodone)
• Opana ER (Oxymorphone)
• Exalgo (Hydromorphone)
• Embeda (Morphine/Naltrexone)
• Hysingla ER (Hydrocodone)
• Suboxone (Buprenorphine/Naloxone) 04/21/23 presentation 61
DISCONTINUE TREATMENT
04/21/23 presentation 62
WHAT WOULD YOU DO?
UPDATED HISTORY
• She returns a year later no better and wishes to stop treatment.
• Currently on Opana ER 40 mg q8h/MSIR 15 mg qid
INITIAL TREATMENT
• Refer to detox unit• Stop the MSIR• Lower LA Opana ER to
30 mg q8h, and reduce monthly
• Lower LA Opana ER to 30 mg q8h, and reduce weekly
04/21/23 presentation 63
WHAT IF THERE IS A PROBLEM OR THEY ARE NOT WORKING?
04/21/23 presentation 64
DEPENDENCE IS NOT ADDICTION
• Physical dependence: – “Physical dependence is a state of
adaptation that is manifested by a drug class specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.”
DISCONTINUING USE OF ER/LA OPIOIDS
• Dependance is not addiction– Withdrawal symptoms include:
• Severe dysphoria• Sweating• Nausea• Rhinorrea• Depression• Severe fatigue• Vomiting • Pain
AVOIDING WITHDRAWAL
DISCONTINUING USE OF ER/LA OPIOIDS
• Tapering recommendations– Variable rate and pattern
• 10% of dose per day to q weekly
– Have a detailed patient agreement• May write out entire schedule?• Removing from clinic/starting other Tx?
– Frequent FU visits• Limit amount of Rx per visit
DISCONTINUING USE OF ER/LA OPIOIDS
• Tapering recommendations– Slow the taper after reaching 1/3 of
original dose– Monitor for withdrawal, worsening pain
or mood and associated function• Objective measures
– Consider urine testing - compliance
WHY ARE YOU TAPERING:COMPLIANCE vs INEFFECTIVENESS?
04/21/23 presentation 70
DISCONTINUING USE OF ER/LA OPIOIDS
• Use SA opioids to complete taper?– The last step off the ER/LA meds– Follow similar % reduction with the
SA meds– Monitor for reduction in mood and
function
II. Initiating Therapy, Modifying Dosing, and Discontinuing Use of ER/LA Opioid Analgesics
• RECOMMENDATIONS
– STRUCTURE
– COMPLIANCE
– DOCUMENTATION
DISCONTINUING USE OF ER/LA OPIOIDS
• DISPOSING OF MEDICATIONS
– FDA INSTRUCTIONS
• FLUSH MEDICATIONS
• DRUG TAKEBACK DAYS
• NEW PHARMACY REGULATIONS
– CONCERNS
• ENVIRONMENTAL
Counseling Patients and Caregivers about the Safe Use of
ER/LA Opioid Analgesics• HOW DO YOU WANT YOUR OFFICE TO
HANDLE ALL OF THIS?– WRITTEN MATERIALS/HANDOUTS/DVD/WEB
• PATIENT COUNSELING FORM• SPECIFIC MEDICATION INFORMATION• SIDE EFFECT AWARENESS• PATIENT AGREEMENT• OFFICE POLICIES
– DRIVING OR OPERATING MACHINERY
– SHOULD THEY SIGN ALL OF THESE?• DOCUMENT THAT THEY RECEIVED THEM ALL?
Counseling Patients and Caregivers about the Safe Use of
ER/LA Opioid Analgesics• HOW DO YOU WANT YOUR OFFICE TO
HANDLE ALL OF THIS?– TELEPHONE POLICIES/ISSUES
• SAME DAY APPOINTMENTS?– MEDICATION NOT WORKING?– SIDE EFFECTS?– THEFT OR LOSS?
• DAYTIME vs NIGHTTIME NUMBERS?• DOCUMANTATION OF PHONE CALLS?
– IS THIS REALLY A GOOD PT TO HAVE ON OPIOIDS?
• HOW OFTEN ARE THEY CALLING?
Counseling Patients and Caregivers about the Safe Use of
ER/LA Opioid Analgesics• HOW DO YOU WANT YOUR OFFICE TO
HANDLE ALL OF THIS?– FOLLOW-UP QUESTIONS
• DID YOU SHARE YOUR MEDS?– ANY LOST OR STOLEN?
• DID YOU BREAK/CHEW/ALTER MEDS OR ADJUST THE DOSE?
• DID YOU DRINK ALCOHOL?• DID ANY OF YOUR OTHER MEDS CHANGE?
– DO WE NEED TO ASK THESE AT EVERY VISIT?• CAN IT BE DONE ON A COMPUTER KIOSK?
WHAT WOULD YOU DO?
I FIND REMS PRINCIPLES:
• Helpful
• Not Helpful
04/21/23 presentation 77
CDC Guideline for Prescribing Opioids (Pre-Decisional)
Dowell, D; Haegerich T, Chou R. (authors)
Background• New CDC guidelines needed to clarify
recommendations based from other groups
• Based on AHRQ systematic review of opioid effectiveness and risks 2014
• Development of clinical practice guidelines with public financing decreases potential for COI
• Scope: non-cancer pain, chronic, > 18 yrs age
• Recommendations into 3 areas (I, II, III) based on 5 clinical questions
I. Determining when to initiate or continue opioids
1. Non-pharmacologic and non-opioid pharmacologic therapy
2. Before initiating, provders should establish realistic goals for pian and functinon and conitinue based on clinically meaninful improvement in pain and function
3. Discussion with patients risks and realistic benieftis of opioid therapy and patient/provider responsibilities for managin pain
II. Opioid selection, dosage, duration, follow-up, and discontinuation
4. When starting opioid therapy, prescirbe short-acting and not ER/LA opioids5. When starting opioids, prescribe lowest effective dose and implement caution when increasing6. When opioids used for acute pain, start with lowest effective dose, and limit treatment duration besides for major surgery7. Providers should evaluate pateints early, and regularly for patients that continue on long-term opioids
III. Assessing risk and addressing harms of opioid use
8. Before starting and during coninuatino, evaluate risks for harms, incorporate into management plans strategies to mitigate risk, inclding offering naloxone9. Review patient’s state PDMP data initially and on regular basis10. Use urine drug testing prior to initiating and on regular basis11. Avoid prescribing opioids and benzodiazepines concurrently12. Offer or arrange evidence-based treatment for patients with opioid use disorder
QUESTIONS